Do Ocugen Inc (NASDAQ: OCGN) Fit In A Value Investing Philosophy?

Currently, there are 287.86M common shares owned by the public and among those 283.54M shares have been available to trade.

The company’s stock has a 5-day price change of -12.84% and -17.27% over the past three months. OCGN shares are trading 69.77% year to date (YTD), with the 12-month market performance up to 144.05% higher. It has a 12-month low price of $0.34 and touched a high of $2.11 over the same period. OCGN has an average intraday trading volume of 5.21 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.89%, -27.30%, and -18.41% respectively.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Institutional ownership of Ocugen Inc (NASDAQ: OCGN) shares accounts for 23.54% of the company’s 287.86M shares outstanding.

It has a market capitalization of $281.01M and a beta (3y monthly) value of 3.73. The earnings-per-share (ttm) stands at -$0.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.21% over the week and 6.56% over the month.

Earnings per share for the fiscal year are expected to increase by 23.08%, and -28.33% over the next financial year.

Looking at the support for the OCGN, a number of firms have released research notes about the stock. Chardan Capital Markets stated their Buy rating for the stock in a research note on March 01, 2023, with the firm’s price target at $3.50. Mizuho coverage for the Ocugen Inc (OCGN) stock in a research note released on August 23, 2022 offered a Buy rating with a price target of $5. ROTH Capital was of a view on June 15, 2022 that the stock is Buy, while Cantor Fitzgerald gave the stock Overweight rating on June 02, 2022, issuing a price target of $4.50. Noble Capital Markets on their part issued Outperform rating on July 26, 2021.

Most Popular

Related Posts